Documentaries, videos and podcasts
July 27, 2021
Artios Pharma has raised $153 million to take its DNA damage response (DDR) pipeline deeper into the clinic. The series C positions Artios, which is run by some of the people behind pioneering DDR drug Lynparza, to test the effect of interfering with DNA double-strand break repair processes.
April 6, 2021
Novartis has struck a deal with Artios Pharma to access DNA damage response (DDR) targets with the potential to enhance its radioligand therapies. Artios, which is run by some of the people behind pioneering DDR drug Lynparza, is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.
February 11, 2021
/PRNewswire/ -- Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the...
December 3, 2020
Germany's Merck is signing up to a small upfront but potentially huge biobucks pact with U.K.-U.S. biotech Artios.